Connect with us

darrens web page full of stuff to help people in health wealth & life in general

darrens web page full of stuff to help people in health wealth & life in general

FDA grants emergency use authorization to Rutgers-developed coronavirus saliva test


Donald Trump

FDA grants emergency use authorization to Rutgers-developed coronavirus saliva test

This story was delivered to Business Insider Intelligence Digital Health Briefing subscribers earlier this morning.To get this story plus others to your inbox each day, hours before they’re published on Business Insider, click here.Stay up-to-date with our latest coverage on the impacts of coronavirus on technology, marketing, and the digital economy here. In the latest sign…

FDA grants emergency use authorization to Rutgers-developed coronavirus saliva test

 In the latest sign the US Food and Drug Administration (FDA) is looking to tackle testing shortages and equip US patients with diagnostic coronavirus tests, the agency granted an emergency use authorization (EUA) for a saliva-based coronavirus test developed by Rutgers University’s RUCDR Infinite Biologics biorepository, according to CNBC. 

The Traditional Patient Journey



Business Insider Intelligence


Saliva-based tests could help ramp up wide-scale coronavirus testing in the US, while protecting frontline healthcare staff and overcoming supply shortages. Rutgers’ test is currently available to the RWJBarnabas Health system in hard-hit New Jersey.

But a larger-scale rollout of the test could be on the horizon, considering the university’s RUCDR lab has the capacity to run 10,000 tests per day and the FDA’s recent EUA should enable other labs to adopt this form of testing, per CNBC. An expanded rollout of Rutgers’ test could help ramp up wide-scale coronavirus testing efforts across the US — which still lags behind other countries such as Italy and Germany in coronavirus tests conducted per million people.

And the nature of Rutgers’ test — which requires individuals with coronavirus symptoms to spit into a cup — could be significant in overcoming testing barriers such as limited supplies and mitigating the spread of the virus among vulnerable healthcare workers. For example, the test eliminates the need for nose and throat swabs — which NYC hospitals currently face a shortage of.

And while healthcare professionals are required to supervise sample collection, the fact that they’re no longer collecting samples themselves limits their potential exposure to the virus and could help hospitals better allocate dwindling supplies of personal protective equipment.

We’re also seeing fast-moving health tech startups like MicroGen DX extending into saliva-based coronavirus testing — but murky home use guidelines could stunt consumer adoption. At-home testing firms’ are also wading into saliva-based coronavirus testing, but their efforts have been hampered by FDA regulatory hurdles, which could further exacerbate the US’ lagging testing efforts.

Texas-based MicroGen DX launched a saliva-based coronavirus test on March 31st for $99. And while the health tech startup indicated its test does not require FDA approval since an accredited lab processes its results, the at-home nature of the test led the FDA to clarify that no coronavirus tests have been authorized for home use, per STAT.

Real Life. Real News. Real Voices

Help us tell more of the stories that matter

Become a founding member

So, while the rollout of at-home diagnostic tests for the novel coronavirus would fill in testing gaps and mitigate the further spread of the virus by arming individuals with the knowledge that they should self-isolate if infected, the sparring between the FDA and health tech startups could put the brakes on testing wide swaths of the US public — and further delay efforts to restart the US economy in the process.

Want to read more stories like this one? Here’s how to get access:

  1. Business Insider Intelligence analyzes the healthcare industry and provides in-depth analyst reports, proprietary forecasts, customizable charts, and more. >> Check if your company has BII Enterprise membership access.
  2. Sign up for the Digital Health Briefing, Business Insider Intelligence’s expert email newsletter tailored for today’s (and tomorrow’s) decision-makers in the healthcare industry, delivered to your inbox 6x a week. >> Get Started
  3. Explore related topics in more depth. >> Visit Our Report Store
  4. Current subscribers can log in to read the briefing here.

Subscribe to the newsletter news

We hate SPAM and promise to keep your email address safe

Click to comment

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Top stories

Facebook

To Top
%d bloggers like this: